Russell Investments Group
KALA icon

Russell Investments Group’s KALA BIO KALA Stock Holding History

Russell Investments Group’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15
Closed -$258K – 3258
2021
Q1 		$258K Buy
+15
New +$293K ﹤0.01% 2764

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Russell Investments Group's KALA Position: Q2 2021 in Review

Russell Investments Group sold out of KALA BIO (KALA) in Q2 2021, closing a stake of 15 shares — an estimated $258K sold.

Russell Investments Group first reported a position in KALA in Q1 2021 and held it in 1 quarter. The position peaked at $258K in Q1 2021. 97 funds tracked by Wall St. Rank hold KALA as of Q2 2021.

  • Russell Investments Group reported no remaining KALA BIO position as of Q2 2021 after selling out during the quarter.
  • Russell Investments Group sold 15 KALA BIO shares in Q2 2021, an estimated $258K.
  • Russell Investments Group first reported a position in KALA BIO in Q1 2021 and held it in 1 quarter.
  • Russell Investments Group's KALA BIO position peaked at $258K in Q1 2021.
  • 97 funds tracked by Wall St. Rank held KALA BIO as of Q2 2021.

Based on Russell Investments Group's 13F filing for Q2 2021, filed 4 Aug 2021.